In vitro and in vivo activity of DQ-2556, a new cephalosporin.
The antibacterial activity of DQ-2556, a new cephalosporin, was compared with that of cefepime, cefpirome, and other antibiotics. DQ-2556 was more active than cefepime and less active than cefpirome against gram-positive bacteria. DQ-2556 was the most active compound against most members of the Enterobacteriaceae, such as Escherichia coli, Klebsiella, Proteus, Salmonella spp., and Shigella spp., and Haemophilus influenzae and Neisseria gonorrhoeae. In vivo, treatment with DQ-2556 was as or more efficacious than that with reference compounds in both systemic and respiratory tract infections in mice. DQ-2556 achieved higher concentrations than cefepime and cefpirome in lungs and kidney of mice.
Ishida
Y
Y
Department of Microbiology, Toho University School of Medicine, Tokyo, Japan.
Miyazaki
S
S
Yamaguchi
K
K
Goto
S
S
D000818:Animals; D001419:Bacteria / Q000187:drug effects*; D001424:Bacterial Infections / Q000188:drug therapy; D002511:Cephalosporins / Q000008:administration & dosage / Q000493:pharmacokinetics / Q000494:pharmacology*; D004755:Enterobacteriaceae / Q000187:drug effects; D008171:Lung Diseases / Q000188:drug therapy; D008297:Male; D051379:Mice; D008826:Microbial Sensitivity Tests
D002511:Cephalosporins; C050465:DQ 2556